Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer

Cancer

Volumn 122, Issue 16, 2016, Pages 2496-2504

  Halpern, Joshua A ^a   Sedrakyan, Art ^a   Hsu, Wei Chun ^a   Mao, Jialin ^a   Daskivich, Timothy J ^b   Nguyen, Paul L ^c   Golden, Encouse B ^a   Kang, Josephine ^a   Hu, Jim C ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

health care costs; prostate cancer; proton beam therapy; radiosurgery; radiotherapy; stereotactic body radiotherapy; toxicity

Indexed keywords

AGED; ARTICLE; BRACHYTHERAPY; CANCER GRADING; CANCER REGISTRY; CONTROLLED STUDY; ERECTILE DYSFUNCTION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HIP FRACTURE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; STEREOTACTIC BODY RADIATION THERAPY; URINARY TRACT DISEASE; URINE INCONTINENCE;

EID: 84982933524     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30101     Document Type: Article

References (34)

1. Tan TJ, Siva S, Foroudi F, Gill S. Stereotactic body radiotherapy for primary prostate cancer: a systematic review. J Med Imaging Radiat Oncol. 2014;58:601–611.
2. Brenner DJ. Toward optimal external-beam fractionation for prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:315–316.
3. Katz AJ, Kang J. Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol. 2014;4:240.
4. Azzam G, Lanciano R, Arrigo S, et al. SBRT: an opportunity to improve quality of life for oligometastatic prostate cancer. Front Oncol. 2015;5:101.
5. Chen LN, Suy S, Uhm S, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013;8:58.
6. Yaeger TE. Accuray company advertising successful prostate cancer treatments with CyberKnife (CK). Int J Radiat Oncol Biol Phys. 2009;73:638–639.
7. Stieber VW. Ethically problematic tactic: advertising CyberKnife as a therapeutic modality to patients (and underinformed clinicians) is inaccurate. Int J Radiat Oncol Biol Phys. 2009;73:638.
8. Meier R. Dose-escalated robotic SBRT for stage I-II prostate cancer. Front Oncol. 2015;5:48.
9. Yu JB, Cramer LD, Herrin J, et al. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol. 2014;32:1195–1201.
10. Hankey BF, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999;8:1117–1121.
11. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV-3–18.
12. Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012;307:1611–1620.
13. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011;29:1517–1524.
14. Cheng L, Montironi R, Bostwick DG, et al. Staging of prostate cancer. Histopathology. 2012;60:87–117.
15. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.
16. American Society for Radiation Oncology. Stereotactic Body Radiation Therapy (SBRT) Model Policy. Arlington, VA: American Society for Radiation Oncology; 2013.
17. Mohler JL, Kantoff PW, Armstrong AJ, et al; National Comprehensive Cancer Network. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014;12:686–718.
18. Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys. 2011;81:1271–1278.
19. Aluwini S, van Rooij P, Hoogeman M, et al. CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance. J Endourol. 2010;24:865–869.
20. King CR, Brooks JD, Gill H, et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:877–882.
21. Katz A, Kang J. Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. Radiat Oncol. 2014;9:1.
22. Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015;314:80–82.
23. Tipton K, Launders JH, Inamdar R, et al. Stereotactic body radiation therapy: scope of the literature. Ann Intern Med. 2011;154:737–745.
24. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA. 1993;269:2633–2636.
25. Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA. 2009;302:1557–1564.
26. Oliai C, Lanciano R, Sprandio B, et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J Radiat Oncol. 2013;2:63–70.
27. Chen LN, Suy S, Wang H, et al. Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat Oncol. 2014;9:148.
28. Katz AJ, Kang J. Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study. Front Oncol. 2014;4:301.
29. Fuller DB. Regarding relative toxicities of stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer. J Clin Oncol. 2014;32:3455–3456.
30. Budaus L, Bolla M, Bossi A, et al. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol. 2012;61:112–127.
31. Sher DJ, Parikh RB, Mays-Jackson S, et al. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer. Am J Clin Oncol. 2014;37:215–221.
32. Amin NP, Sher DJ, Konski AA. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013. Appl Health Econ Health Policy. 2014;12:391–408.
33. Parthan A, Pruttivarasin N, Davies D, et al. Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. Front Oncol. 2012;2:81.
34. Laviana AA, Ilg AM, Veruttipong D, et al. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer. Cancer. 2016;122:447–455.